IRVINE, Calif., Oct. 7, 2020 /PRNewswire/ -- Today Allergan
Aesthetics, an AbbVie company (NYSE: ABBV), announced that it
has entered into an agreement with Luminera, a privately held,
aesthetics company based in Israel
with a portfolio and pipeline of dermal filler products.
Under the terms of the agreement, Allergan Aesthetics will
acquire Luminera's full dermal filler portfolio and R&D
pipeline further enhancing Allergan Aesthetics' leading dermal
filler portfolio with its JUV DERM® collection of
fillers.
"The addition of the Luminera assets adds innovative technology,
complementing our leading JUV DERM® filler
franchise. We welcome the Luminera team as we continue to
build our global aesthetics company and a world-class product
offering for healthcare professionals and patients around the
world," said Carrie Strom, SVP,
AbbVie, and President, Global Allergan Aesthetics.
Luminera Chairman Dadi Segal,
PhD, added, "We believe bringing together key, innovative Luminera
assets with the support of Allergan Aesthetics will provide an even
brighter future for our people, products and a more expanded
offering for our customers. This is a tremendous opportunity
to further build, develop and collaborate with a leading global
aesthetics company."
Luminera's key value driver for the future is HArmonyCa, an
innovative dermal filler intended for facial soft tissue
augmentation comprised of a combination of cross-linked hyaluronic
acid (HA) with embedded calcium hydroxyapatite (CaHA)
microspheres. The combination of HA and CaHA in a single
product is highly differentiated in the dermal filler
category. HArmonyCa is currently commercially available in
Israel and Brazil.
Allergan Aesthetics will continue to develop this product for
its International and US markets.
The Luminera dermal filler portfolio also includes a line of HA
dermal fillers, as well CaHA based fillers commercialised across
several markets. Brands include Crystalys, Hydryalix and
Hydryal.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop,
manufacture, and market a portfolio of leading aesthetics brands
and products. Our aesthetics portfolio includes facial injectables,
body contouring, plastics, skin care, and more. Our goal is to
consistently provide our customers with innovation, education,
exceptional service, and a commitment to excellence, all with a
personal touch. For more information,
visit www.AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original
content:http://www.prnewswire.com/news-releases/allergan-aesthetics-an-abbvie-company-acquires-innovative-luminera-dermal-filler-business-301147404.html
SOURCE AbbVie